Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors PANCREAS Kunz, P. L., Reidy-Lagunes, D., Anthony, L. B., Bertino, E. M., Brendtro, K., Chan, J. A., Chen, H., Jensen, R. T., Kim, M. K., Klimstra, D. S., Kulke, M. H., Liu, E. H., Metz, D. C., Phan, A. T., Sippel, R. S., Strosberg, J. R., Yao, J. C. 2013; 42 (4): 557-577


Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.

View details for DOI 10.1097/MPA.0b013e31828e34a4

View details for PubMedID 23591432